Phaseline

Companies › Oncolytics Biotech

Oncolytics Biotech: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Pelareorep
Oncolytic reovirus
–Phase 2Breast Cancer Metastatic; Ras-mutated Metastatic Colorectal Cancer; Anal Cancer Metastatic; Anatomic Stage IV Breast Cancer AJCC v8 …Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04215146PelareorepPhase 2Breast Cancer MetastaticOncologyAug 2022
NCT04445844PelareorepPhase 2Anatomic Stage IV Breast Cancer AJCC v8OncologyJun 2025
NCT05514990PelareorepPhase 1Recurrent Plasma Cell MyelomaOncologyDec 2026
NCT07280377PelareorepPhase 1Anal Cancer MetastaticOncologyJul 2027
NCT07446322PelareorepPhase 2Ras-mutated Metastatic Colorectal CancerOncologyAug 2027

From the company's SEC filings

Cash of $4m on 2026-06-30; operating cash outflow about $31m a year; runway about 2 months at that burn, to Aug 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cardiff Oncology TuHURA Biosciences Actuate Therapeutics Inhibrx Biosciences Genelux

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.